Journal of Gynecologic Oncology

Korean Society of Gynecologic Oncology (대한부인종양학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases

Jang, Hyunsoo;Chun, Mison;Cho, Oyeon;Heo, Jae Sung;Ryu, Hee-Sug;Chang, Suk-Joon

  • Published : 20130700
⟨ Previous Next ⟩

Abstract

Objective: The purpose of the present study was to evaluate treatment outcomes and prognostic factors in cervical cancer patients with isolated para-aortic lymph node (PALN) metastases. We especially tried to evaluate PALN factors such as size, site and number. Methods: From August 1994 to December 2009, 40 cervical cancer patients with isolated PALN node metastases at initial diagnosis were selected for analysis. Patients underwent both extended field external beam and intracavitary brachytherapy. Fourteen patients received 5-fluorouracil and cisplatin (FP) and 16 patients received weekly concurrent cisplatin. Information of PALN, such as size, site, and number, was founded before PALN radiotherapy. Results: The median follow-up time after primary treatment was 28.5 months (range, 2 to 213 months). The 3-year overall and progression-free survival rate after primary treatment was 44.3% and 31.3%, respectively. In multivariate analysis including tumor stage, performance status, and chemotherapy, FP regimen concurrent chemoradiotherapy was more effective than radiotherapy alone (p=0.030). The 3-year progression-free survival rate was 41.9% and 11.1% in patients with PALN numbers of ${\leq}1$ and ${\geq}2$, respectively (p=0.008). The 3-year progression-free survival rate was 42.1% and 19.2% in patients with PALN size of <1.5 cm and ${\geq}1.5$ cm, respectively (p=0.031). Conclusion: The radiologic features of PALN, such as number or size, can be used to determine prognosis in PALN metastatic cervical cancer patients. Furthermore, FP regimen concurrent chemoradiotherapy was associated with better patient survival than radiotherapy alone. However, more studies are required to confirm possible different treatment outcomes between FP and weekly cisplatin regimens.

Keywords

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6. https://doi.org/10.1002/ijc.1440
  2. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in Oncology [Internet]. Fort Washington, PA: NCCN; 2013 [cited 2013 May 20]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  3. Sakurai H, Mitsuhashi N, Takahashi M, Akimoto T, Muramatsu H, Ishikawa H, et al. Analysis of recurrence of squamous cell carcinoma of the uterine cervix after definitive radiation therapy alone: patterns of recurrence, latent periods, and prognosis. Int J Radiat Oncol Biol Phys 2001;50:1136-44. https://doi.org/10.1016/S0360-3016(01)01573-5
  4. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6. https://doi.org/10.1016/0360-3016(95)00060-C
  5. Singh AK, Grigsby PW, Rader JS, Mutch DG, Powell MA. Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence. Int J Radiat Oncol Biol Phys 2005;61:450-5. https://doi.org/10.1016/j.ijrobp.2004.06.207
  6. Rajasooriyar C, Van Dyk S, Bernshaw D, Kondalsamy-Chennakesavan S, Barkati M, Narayan K. Patterns of failure and treatment-related toxicity in advanced cervical cancer patients treated using extended field radiotherapy with curative intent. Int J Radiat Oncol Biol Phys 2011;80:422-8. https://doi.org/10.1016/j.ijrobp.2010.02.026
  7. Varia MA, Bundy BN, Deppe G, Mannel R, Averette HE, Rose PG, et al. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 1998;42:1015-23. https://doi.org/10.1016/S0360-3016(98)00267-3
  8. Grigsby PW, Heydon K, Mutch DG, Kim RY, Eifel P. Long-term follow-up of RTOG 92-10: cervical cancer with positive paraaortic lymph nodes. Int J Radiat Oncol Biol Phys 2001;51:982-7. https://doi.org/10.1016/S0360-3016(01)01723-0
  9. Kim YS, Shin SS, Nam JH, Kim YT, Kim YM, Kim JH, et al. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecol Oncol 2008;108:195-200. https://doi.org/10.1016/j.ygyno.2007.09.022
  10. Kong TW, Chang SJ, Paek J, Yoo SC, Yoon JH, Chang KH, et al. Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer. J Gynecol Oncol 2012;23:235-41. https://doi.org/10.3802/jgo.2012.23.4.235
  11. Zighelboim I, Taylor NP, Powell MA, Gibb RK, Rader JS, Mutch DG, et al. Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy. Radiat Med 2006;24:625-30. https://doi.org/10.1007/s11604-006-0082-6
  12. Micke O, Bruns F, Schafer U, Prott FJ, Willich N. The impact of squamous cell carcinoma (SCC) antigen in patients with advanced cancer of uterine cervix treated with (chemo-) radiotherapy. Anticancer Res 2005;25:1663-6.
  13. Hong JH, Tsai CS, Chang JT, Wang CC, Lai CH, Lee SP, et al. The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:823-30. https://doi.org/10.1016/S0360-3016(98)00147-3

Cited by

  1. Management of cervical cancer patients with isolated para-aortic lymph node metastases vol.24, pp.4, 2013, https://doi.org/10.3802/jgo.2013.24.4.382
  2. Reply to JY Lee vol.24, pp.4, 2013, https://doi.org/10.3802/jgo.2013.24.4.383
  3. Trial Watch: Radioimmunotherapy for oncological indications vol.3, pp.9, 2013, https://doi.org/10.4161/21624011.2014.954929
  4. Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparaoscopic lymphadenectomy vol.191, pp.5, 2013, https://doi.org/10.1007/s00066-014-0785-z
  5. Extended Field Radiotherapy With or Without Chemotherapy in Patients with Cervical Cancer and Positive Para-Aortic Lymph Nodes: a Single Institution Retrospective Review vol.16, pp.9, 2015, https://doi.org/10.7314/apjcp.2015.16.9.3827
  6. Advances in diagnosis and treatment of metastatic cervical cancer vol.27, pp.4, 2013, https://doi.org/10.3802/jgo.2016.27.e43
  7. Nomograms predicting survival and patterns of failure in patients with cervical cancer treated with concurrent chemoradiotherapy: A special focus on lymph nodes metastases vol.14, pp.4, 2013, https://doi.org/10.1371/journal.pone.0214498
  8. Para-aortic lymph node surgical staging in locally-advanced cervical cancer: comparison between robotic versus conventional laparoscopy vol.30, pp.4, 2013, https://doi.org/10.1136/ijgc-2019-000961
  9. Cost-Effectiveness Analysis of Diagnostic Tests for Para-Aortic Lymph Node Detection in Locally Advanced Cervical Cancer vol.13, pp.None, 2013, https://doi.org/10.2147/ceor.s327698